RxDoctor Payments DataLook up a doctor →

Cynthia Rivera, MD

Infectious Disease · Miami Beach, FLNPI 1285835520

Payments from drug & device makers

$311,592in general payments, 2019–2025

Across 915 payments — averaging $340.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$119K
  • Viiv Healthcare Company$93K
  • Theratechnologies Inc.$49K
  • Aimmune Therapeutics, Inc.$36K
  • AbbVie$6K
  • Tetraphase Pharmaceuticals, Inc.$3K
  • plus $4K from 19 others

What the payments were for

  • Consulting fees$93,06535%
  • Speaking & faculty fees$126,50348%
  • Travel & lodging$25,46510%
  • Food & beverage$20,0298%
  • Education$3250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$311,592 in reported general payments places this provider in the 95th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$13,018
Medicare patients
63
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala351$1,471,243
DovatoDolutegravir Sodium/Lamivudine183$559,398
SerostimSomatropin12$251,588
CabenuvaCabotegravir/Rilpivirine18$122,413
RukobiaFostemsavir Tromethamine13$114,787
TivicayDolutegravir Sodium42$106,913
JulucaDolutegravir/Rilpivirine20$90,226
Egrifta SvTesamorelin Acetate11$80,959
DescovyEmtricitabine/Tenofov Alafenam26$59,649
PrezcobixDarunavir/Cobicistat12$34,273
Maraviroc13$17,629
ValacyclovirValacyclovir Hcl36$1,040
Methenamine Hippurate13$924
Testosterone12$901
Doxycycline Hyclate36$489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$119,448$1,530,893377 claims
Viiv Healthcare CompanyDovato, Cabenuva, Rukobia, Tivicay, Juluca$93,324$993,737276 claims
EMD Serono, Inc.Serostim$105$251,58812 claims
Theratechnologies Inc.Egrifta Sv$48,579$80,95911 claims
Johnson & JohnsonPrezcobix$1,105$34,27312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →